Successful treatment of refractory autoimmune hepatitis with rituximab

Pediatrics

Volumn 132, Issue 2, 2013, Pages

  D'Agostino, Daniel ^a   Costaguta, Alejandro ^b   Alvarez, Fernando ^c  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b Sanatorio de Ninos Rosario   (Argentina)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Autoimmune hepatitis; Children; Rituximab; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CYCLOSPORIN; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; SERUM ALBUMIN; SMOOTH MUSCLE ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE HEPATITIS; CASE REPORT; CHILD; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LIVER FIBROSIS; LIVER HISTOLOGY; PRIORITY JOURNAL; PRURITUS; REMISSION; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT;

EID: 84882288376     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-1900     Document Type: Article

References (12)

1. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354(1):54-66
2. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18(4):998-1005
3. Alvarez F. Autoimmune hepatitis and primary sclerosing cholangitis. Clin Liver Dis. 2006;10(1):89-107, vi [vi.
4. Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010; 149(1):3-13
5. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut. 1998;42(5):721-726
6. Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999;116(3):643-649
7. Ma Y, Bogdanos DP, Hussain MJ, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology. 2006;130(3):868-882
8. Santos ES, Arosemena LR, Raez LE, O'Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int. 2006;26(5):625-629
9. Miloh T, Manwani D, Morotti R, Sukru E, Shneider B, Kerkar N. Giant cell hepatitis and autoimmune hemolytic autoimmune anemia successfully treated with rituximab. J Pediatr Gastroenterol Nutr. 2007;44 (5):634-636
10. Shores D, Kobak G, Pegram LD, Whitington PF, Shneider BL. Giant cell hepatitis and immune thrombocytopenic purpura: reversal of liver failure with rituximab therapy. J Pediatr Gastroenterol Nutr. 2012;55 (4):e128-e130
11. Maggiore G, Sciveres M, Fabre M, et al. Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: longterm outcome in 16 children. J Pediatr. 2011;159(1):127-132.e1
12. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;10(8):816-824